➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 8,071,645

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 8,071,645
Title:Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.
Inventor(s): Newell; M. Karen (Colorado Springs, CO), Newell; Evan (Toronto, CA), Villalobos-Menuey; Elizabeth (Colorado Springs, CO)
Assignee: The Regents of the University of Colorado (Denver, CO)
Application Number:10/866,141
Patent Claims:see list of patent claims

Details for Patent 8,071,645

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 2019-02-28 ⤷  Free Forever Trial The Regents of the University of Colorado (Denver, CO) 2023-06-12 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 1998-09-25 ⤷  Free Forever Trial The Regents of the University of Colorado (Denver, CO) 2023-06-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.